Ami Bhatt and Michael Mack explain the economics of AI use in the detection of subclinical cardiovascular disease.
For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback